Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 50, Issue 1, 2000, Pages 161-177

  Müller, Rainer H ^a   Mäder, Karsten ^a   Gohla, Sven ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bioavailability enhancer; Colloidal drug carrier; Controlled release; Solid lipid nanoparticles; Vaccine adjuvant

Indexed keywords

ACICLOVIR; ADJUVANT; ALPHA TOCOPHEROL; AMPHOTERICIN; ASCORBIC ACID; BROMOCRIPTINE MESILATE; CAMPTOTHECIN; CORTISONE; CYCLOSPORIN A; DIAZEPAM; DOXORUBICIN; DRUG; DRUG CARRIER; ETOMIDATE; IDARUBICIN; LEUPRORELIN; LIPID; MENADIONE; NANOPARTICLE; OXAZEPAM; PACLITAXEL; PILOCARPINE; PREDNISOLONE; PROGESTERONE; RETINOL; SUNSCREEN; TETRACAINE; TIMOLOL; TRIPTORELIN; UBIDECARENONE; UNINDEXED DRUG;

CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG RELEASE; PARTICLE SIZE; REVIEW;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; MICROSPHERES;

EID: 0038032150     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(00)00087-4     Document Type: Review

References (126)

1. Müller R.H., Hildebrand G.E. Pharmazeutische Technologie: Moderne Arzneiformen, Lehrbuch für Studierende der Pharmazie-Nachschlagewerk für Apotheker in Offizin, Krankenhaus und Forschung. 2. Erweiterte Aufl. 1998;Wissenschaftliche Verlagsgesellschaft, Stuttgart.
2. Schmitt J. Parenterale Fettemulsionen als Arzneistoffträger. Müller R.H., Hildebrand G.E. Pharmazeutische Technologie: Moderne Arzneiformen. 1998;189-194 Wissenschaftliche Verlagsgesellschaft, Stuttgart.
3. Diederichs J.E., Müller R.H. Liposome in Kosmetika und Arzneimitteln. Pharm. Ind. 56:1994;267-275.
4. Fahr A., Kissel T. Mikropartikel und Implantate: Arzneiformen zur parenteralen Applikation. Müller R.H., Hildebrand G.E. Pharmazeutische Technologie: Moderne Arzneiformen. 1998;243-258 Wissenschaftliche Verlagsgesellschaft, Stuttgart.
5. Smith A., Hunneyball I.M. Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int. J. Pharm. 30:1986;215-220.
6. Müller R.H., Maaßen S., Weyhers H., Specht F., Lucks J.S. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int. J. Pharm. 138:1996;85-94.
7. R.H. Müller, J.S. Lucks, Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN), European Patent No. 0605497 (1996).
8. M.R. Gasco, Method for producing solid lipid microspheres having a narrow size distribution, US Patent 5 250 236 (1993).
9. Siekmann B., Westesen K. Sub-micron sized parenteral carrier systems based on solid lipid. Pharm. Pharmacol. Lett. 1:1992;123-126.
10. Müller R.H., Mehnert W., Lucks J.S., Schwarz C., zur Mühlen A., Weyhers H., Freitas C., Rühl D. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41:1995;62-69.
11. Siekmann B., Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination. Pharm. Pharmacol. Lett. 3:1994;194-197.
12. Siekmann B., Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. II. Physicochemical characterization and lyophilisation. Pharm. Pharmacol. Lett. 3:1994;225-228.
13. Müller R.H., Runge S.A. Solid lipid nanoparticles (SLN®) for controlled drug delivery. Benita S. Submicron Emulsions in Drug Targeting and Delivery. 1998;219-234.
14. Cavalli R., Marengo E., Rodriguez L., Gasco M.R. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 43:1996;110-115.
15. Cavalli R., Caputo O., Carlotti M.E., Trotta M., Scarnecchia C., Gasco M.R. Sterilisation and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 148:1997;47-54.
16. Bocca C., Caputo O., Cavalli R., Gabriel L., Miglietta A., Gasco M.R. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int. J. Pharm. 175:1998;185-193.
17. Cavalli R., Bocca C., Miglietta A., Caputo O., Gasco M.R. Albumin adsorption on stealth and non-stealth solid lipid nanoparticles. S.T.P. Pharma Sci. 9:1999;183-189.
18. Heiati H., Phillips N.C., Tawashi R. Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm. Res. 13:1996;1406-1410.
19. Heiati H., Tawashi R., Shivers R.R., Phillips N.C. Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate. Int. J. Pharm. 146:1997;123-131.
20. Heiati H., Tawashi R., Phillips N.C. Solid lipid nanoparticles as drug carriers. II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate in mice. Int. J. Pharm. 174:1998;71-80.
21. Heiati H., Tawashi R., Phillips N.C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving storage and lyophilization. J. Microencapsulation. 15:1998;173-184.
22. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release. 59:1999;299-307.
23. Yang S., Zhu J., Lu Y., Liang B., Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 16:1999;751-757.
24. Lukowski G., Pflegel P. Electron diffraction of solid lipid nanoparticles loaded with aciclovir. Pharmazie. 52:1997;642-643.
25. Lukowski G., Werner U., Pflegel P. Surface investigation and drug release of drug-loaded solid lipid nanoparticles. Proc. 2nd World Meeting APGI/APV. 1998;573-574.
26. Lukowski G., Werner U. Investigation of surface and drug release of solid lipid nanoparticles loaded with aciclovir. Proc. Int. Symp. Control. Release Bioact. Mater. 25:1998;425-426.
27. Lukowski G., Werner U., Kasbohm J. Electron diffraction of solid lipid nanoparticles loaded with aciclovir. Proc. Int. Symp. Control. Release Bioact. Mater. 25:1998;431-432.
28. Demirel M., Yazan Y., Müller R.H., Kilic F., Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid particles. J. Microencapsulation. 2000;submitted.
29. Ahlin P., Kristl J., Šentjurc M. study of loading capacity and location of spin-labeled lipophilic substance in different SLN. Int. Symp. Control. Release Bioact. Mater. 25:1998;334-335.
30. Ahlin P., Šentjurc M., Štrancar J., Kristl J. Location of lipophilic substances and ageing of solid lipid nanoparticles studied per EPR. S.T.P. Pharma Sci. 2000;submitted.
31. de Vringer T., de Ronde H.A.G. Preparation and structure of a water-in-oil cream containing lipid nanoparticles. J. Pharm. Sci. 84:1995;466-472.
32. Müller R.H., Dobrucki R., Radomska A. Solid lipid nanoparticles as a new formulation with retinol. Acta Polonica Pharmaceutica-Drug Res. 56:1999;117-120.
33. Müller R.H., Heinemann S. Fat emulsions for parenteral nutrition IV: Lipofundin MCT/LCT regimens for total parenteral nutrition (TPN) with high electrolyte load. Int. J. Pharm. 107:1994;121-132.
34. Iscan Y.Y., Hekimoglu S., Kas S., Hincal A.A. Formulation and characterization of solid lipid nanoparticles for skin delivery, conference 'lipid and surfactant dispersed systems'. Moscow, Proceedings Book. 1999;163-166.
35. zur Mühlen A., zur Mühlen E., Niehus H., Mehnert W. Atomic force microscopy studies of solid lipid nanoparticles. Pharm. Res. 13:1996;1411.
36. Schwarz C., Mehnert W., Lucks J.S., Müller R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilisation. J. Control. Release. 30:1994;83-96.
37. zur Mühlen A., Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie. 53:1998;552.
38. Eldem T., Speiser P., Hincal A. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm. Res. 8:1991;47-54.
39. P. Speiser, Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung, European Patent EP 0167825 (1990).
40. Müller R.H., Schwarz C., Mehnert W., Lucks J.S. Production of solid lipid nanoparticles (SLN) for controlled drug delivery. Proc. Int. Symp. Control. Release Bioact. Mater. 20:1993;480-481.
41. Müller B.W. Mikroemulsionen als neue Wirkstoff-Trägersysteme. Müller R.H., Hildebrand G.E. Pharmazeutische Technologie: Moderne Arzneiformen. 1998;161-168 Wissenschaftliche Verlagsgesellschaft, Stuttgart.
42. Gasco M.R. Solid lipid nanospheres from warm micro-emulsions. Pharm. Technol. Eur. 9:1997;52-58.
43. Boltri L., Canal T., Esposito P.A., Carli F. Lipid nanoparticles: evaluation of some critical formulation parameters. Proc. Int. Symp. Control. Release Bioact. Mater. 20:1993;346-347.
44. Morel S., Terreno E., Ugazio E., Aime S., Gasco M.R. NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium (III) complexes. Eur. J. Pharm. Biopharm. 45:1998;157-163.
45. e Rencentre Pharmapeptides. 1999.
46. H. Weyhers, Feste Lipid-Nanopartikel (SLN) für die gewebsspezifische Arzneistoffapplikation, Ph.D. thesis, Free University of Berlin (1995).
47. A.J. Domb, Lipospheres for controlled delivery of substances, US Patent 5 188 837 (1993).
48. Domb A.J., Marlinsky A., Maniar M., Teomim L. Insect repellent formulations of N, N-diethyl-m-toluamide (deet) in a liposphere system: efficacy and skin uptake. J. Am. Mosquito Control Assoc. 11:1995;29-34.
49. Domb A.J. Long acting injectable oxytetracycline-liposphere formulations. Int. J. Pharm. 124:1995;271-278.
50. Westesen K., Siekmann B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int. J. Pharm. 151:1997;35-45.
51. Siekmann B., Westesen K. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur. J. Pharm. Biopharm. 43:1996;104-109.
52. Westesen K., Bunjes H., Koch M.H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release. 48:1997;223-236.
53. Schwarz C., Freitas C., Mehnert W., Müller R.H. Sterilisation and physical stability of drug-free and etomidate-loaded solid lipid nanoparticles. Proc. Int. Symp. Control. Release Bioact. Mater. 22:1995;766-767.
54. C. Schwarz, Feste Lipidnanopartikel: Herstellung, Charakterisierung, Arzneistoffinkorporation und -freisetzung, Sterilisation und Lyophilisation, Ph.D. thesis, Free University of Berlin (1995).
55. Jenning V., Gysler A., Schäfer-Korting M., Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug penetration into porcine skin. Eur. J. Pharm. Biopharm. 2000;. in press.
56. Jenning V., Schäfer-Korting M., Gohla S. Vitamin A loaded solid lipid nanoparticles for topical application: drug release properties. J. Control. Release. 2000;. in press.
57. V. Jenning, Feste Lipid Nanopartikel als Trägersystem für die dermale Applikation von Retinol, Ph.D. thesis, Free University of Berlin (1999).
58. A. Dingler, Feste Lipid-Nanopartikel als kolloidale Wirkstoffträgersysteme zur dermalen Applikation, Ph.D. thesis, Free University of Berlin (1998).
59. S.A. Runge, Feste Lipid-Nanopartikel (SLN) als kolloidaler Arzneistoffträger für Cyclosporin A, Ph.D. thesis, Free University of Berlin (1998).
60. L. Penkler, R.H. Müller, S.A. Runge, V. Ravelli, Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation, WO 99/56733 (1999).
61. Mehnert W., zur Mühlen A., Dingler A., Weyhers H., Müller R.H. Solid Lipid Nanoparticles (SLN) - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika. II. Wirkstoff-Inkorporation, Freisetzung und Sterilizierbarkeit. Pharm. Ind. 1997;511-514.
62. Westesen K., Siekmann B., Koch M.H.J. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int. J. Pharm. 93:1993;189-199.
63. Bunjes H., Westesen K., Koch M.H.J. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 129:1996;159-173.
64. 1H-NMR study. Int. J. Pharm. 2000;submitted.
65. Jenning V., Gohla S. Characterisation of solid lipid nanoparticles (SLN) based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000;submitted.
66. Cavalli R., Peira E., Caputo O., Gasco M.R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int. J. Pharm. 182:1999;59-69.
67. A. zur Mühlen, Feste Lipid Nanopartikel mit prolongierter Wirkstoffliberation-Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und -mechanismen, Ph.D. thesis, Free University of Berlin (1996).
68. zur Mühlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. Eur. J. Pharm. Biopharm. 45:1998;149-155.
69. C. Schwarz, Feste Lipidnanopartikel: Herstellung, Charakterisierung, Arzneistoffinkorporation and -freisetzung, Sterilization und Lyophilisation, Ph.D. thesis, Free University of Berlin (1995).
70. Garti N., Sato K. Crystallization and Polymorphism of Fats and Fatty Acids. 1998;Marcel Dekker, New York and Basel.
71. Anger S., Caldwell K., Niehus H., Müller R.H. High resolution size determination of 20 nm colloidal gold particles by sedimentation field flow fractionation. Pharm. Res. 16:1999;1743-1747.
72. Anger S., Caldwell K.D., Müller R.H. Charakterisierung von Molekülen, Kolloiden und Partikeln mit der Field Flow Fractionation. Pharm. Ind. 62:2000;150-156.
73. Anger S., Mehnert W., Caldwell K., Müller R.H. High Resolution Determination of Adsorption Layer Mass on Particles by Sedimentation Field-Flow Fractionation. Proc. 2nd World Meeting APGI/APV. 1998;643-644.
74. Anger S., Caldwell K., Mehnert W., Müller R.H. Coating of nanoparticles: analysis of adsorption using sedimentation field-flow fractionation (SdFFF). Proc. Int. Symp. Control. Release Bioact. Mater. 1999;26.
75. Müller R.H. Zetapotential und Partikelladung-Kurze Theorie, praktische Meßdurchführung, Dateninterpretation. 1996;Wissenschaftliche Verlagsgesellschaft, Stuttgart.
76. Zimmermann E., Liedtke S., Müller R.H., Mäder K. H-NMR as a method to characterize colloidal carrier systems. Proc. Int. Symp. Control. Release Bioact. Mater. 26:1999;591-592.
77. Liedtke S., Zimmermann E., Müller R.H., Mäder K. Physical characterisation of solid lipid nanoparticles (SLN™). Proc. Int. Symp. Control. Release Bioact. Mater. 26:1999;595-596.
78. C. Olbrich, Entwicklung optimierter Lipidcarrier und ihre Untersuchung in biologischen Systemen, Ph.D. thesis, Free University of Berlin (2000).
79. Maaßen S., Schwarz C., Mehnert W., Lucks J.S., Yunis-Specht F., Müller B.W., Müller R.H. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (SLN). Proc. Int. Symp. Control. Release Bioact. Mater. 20:1993;490-491.
80. Weyhers H., Ehlers S., Mehnert W., Hahn H., Müller R.H. Solid Lipid Nanoparticles-Determination of In Vivo Toxicity. Proc. 1st World Meeting APGI/APV. 1995;489-490.
81. Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanospheres carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharm. Res. 1999;submitted.
82. Müller R.H., Dingler A. Feste Lipid-Nanopartikel (Lipopearls™) als neuartiger Carrier für kosmetische und dermatologische Wirkstoffe. Pharmazeutische Zeitung Dermopharmazie. 1998;11-15.
83. Müller R.H., Dingler A. The next generation after the liposomes: solid lipid nanoparticles (SLN™, Lipopearls™) as dermal carrier in cosmetics. Eurocosmetics. 7/8:1998;19-26.
84. Wissing S., Mäder K., Rogaschewski S., Müller R.H. Solid lipid nanoparticles (SLN) - a novel carrier for UV-blockers. Int. J. Pharm. 2000;submitted.
85. Dingler A., Hildebrand G., Niehus H., Müller R.H. Cosmetic anti-aging formulation based on vitamin E-loaded solid lipid nanoparticles. Proc. Int. Symp. Control. Release Bioact. Mater. 25:1998;433-434.
86. Jenning V., Gohla S., Müller R.H. Solid lipid nanoparticles (SLN): effect of homogenization parameters on drug stability. Proc. 2nd World Meeting APGI/APV. 1998;619-620.
87. Müller R.H., Dingler A., Weyhers H., zur Mühlen A., Mehnert W. Solid Lipid Nanoparticles (SLN)-ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika. III. Langzeitstabilität, Gefrier- und Sprühtrocknung, Anwendung in Kosmetika und Pharmazeutika. Pharm. Ind. 1997;614-619.
88. Pinto J.F., Müller R.H. Pellets as carriers of solid lipid nanoparticles (SLN™) for oral administration of drugs. Die Pharmazie. 1999;506-509.
89. A. Lippacher, Flüssig und halbfeste SLN-Dispersionen zur topischen Applikation, Ph.D. thesis, Free University of Berlin (2001).
90. Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of loperamide across the blood-brain barrier with Polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14:1997;325-328.
91. R.H. Müller, M. Lück, J. Kreuter, Arzneistoffträgerpartikel für die gewebsspezifische Arzneistoffapplikation, German patent application No.197 45 950.1 (1997).
92. Müller R.H., Olbrich C. Kayser O., Müller R.H. Neue Adjuvantien in der Impfstofftechnologie, Pharmazeutische Biotechnologie. 2000;278-298 Wissenschaftliche Verlagsgesellschaft, Stuttgart.
93. Olbrich C., Müller R.H. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm. 1999;31-39.
94. Olbrich C., Mehnert W., Müller R.H. Effect of surfactant and lipid composition on the in vitro degradation time of solid lipid nanoparticles (SLN). Proc. Int. Symp. Control. Release Bioact. Mater. 24:1997;921-922.
95. Olbrich C., Mehnert W., Müller R.H. In Vitro Degradation Properties of Solid Lipid Nanoparticles™ SLN. Proc. 2nd World Meeting APGI/APV. 1998;577-578.
96. Hildebrand G.E., Dingler A., Runge S.A., Müller R.H. Medium scale production of solid lipid nanoparticles (SLN). Proc. Int. Symp. Control. Release Bioact. Mater. 25:1998;968-969.
97. Müller R.H., Dingler A., Schneppe T., Gohla S. Large scale production of solid lipid nanoparticles (SLN™) and nanosuspensions (DissoCubes™). Wise D. Handbook of Pharmaceutical Controlled Release Technology. 2000;Marcel Dekker Inc, New York. in press.
98. Siekmann B., Westesen K. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloids and Surfaces B: Biointerfaces. 3:1994;159-175.
99. Siekmann B., Westesen K. Preparation and physicochemical characterization of aqueous dispersions of coenzyme Q10 nanoparticles. Pharm. Res. 12:1995;201-208.
100. Westesen K., Bunjes H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int. J. Pharm. 115:1995;129-131.
101. Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J. Microencapsulation. 16:1999;205-213.
102. Cavalli R., Gasco M.R., Morel S. Behaviour of timolol incorporated in lipospheres in the presence of a series of phosphate esters. S.T.P. Pharma Sci. 2:1992;514-518.
103. Gasco M.R., Morel S., Carpignano R. Optimization of the incorporation of deoxycorticosterone acetate in lipospheres. J. Pharm. Biopharm. 38:1992;7-10.
104. Gasco M.R., Cavalli R., Carlotti M.E. Timolol in lipospheres. Pharmazie. 47:1992;119-121.
105. Aquilano D., Cavalli R., Gasco M.R. Solid lipospheres obtained from hot microemulsions in the presence of different concentrations of cosurfactant: the crystallization of stearic acid polymorphs. Thermochim. Acta. 230:1993;29-37.
106. Cavalli R., Caputo O., Gasco M.R. Solid lipospheres of doxorubicin and idarubicin. Int. J. Pharm. 89:1993;R9-R12.
107. Morel S., Gasco M.R., Cavalli R. Incorporation in lipospheres of [D-Trp-6]LHRH. Int. J. Pharm. 105:1994;R1-R3.
108. Cavalli R., Morel S., Gasco M.R., Chetoni P., Saettone M.F. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int. J. Pharm. 117:1995;243-246.
109. Morel S., Ugazio E., Cavalli R., Gasco M.R. Thymopentin in solid lipid nanoparticles. Int. J. Pharm. 132:1996;259-261.
110. Cavalli R., Marengo E., Caputo O., Ugazio E., Gasco M.R. The effect of alcohols with different structures on the formation of warm o/w microemulsions. J. Dispersion Sci. Technol. 17:1996;717-734.
111. Diederichs J.E., Müller R.H. Future Strategies for Drug Delivery with Particulate Systems. 1998;Wissenschaftliche Verlagsgesellschaft, Stuttgart.
112. Müller R.H., Maaßen S., Weyhers H., Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with Poloxamine 908 and Poloxamer 407. J. Drug Targeting. 4:1996;161-170.
113. Müller R.H., Maaßen S., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) formulation for human use: interaction with human granulocytes. J. Control. Release. 47:1997;261-269.
114. Rühl D., Schulze-Forster K., Müller R.H. Interaction of differentiated HL60 cells with Poloxamer and Poloxamine surface modified model drug carriers. Eur. J. Pharm. Biopharm. 5:1996;147-153.
115. Müller R.H., Rühl D., Runge S. Biodegradation of SLN as a function of lipase incubation time. Int. J. Pharm. 144:1997;115-121.
116. Müller R.H., Rühl D., Runge S., Schulze-Forster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14:1997;458-462.
117. Müller R.H., Weyhers H., zur Mühlen A., Dingler A., Mehnert W. Solid Lipid Nanoparticles (SLN) - ein neuartiger Wirkstoff-Carrier für Kosmetika und Pharmazeutika. I. Systemeigenschaften, Herstellung und Scaling up. Pharm. Ind. 59:1997;423-427.
118. Freitas C., Müller R.H. Spray drying of solid lipid nanoparticles (SLN™). Eur. J. Pharm. Biopharm. 46:1998;145-151.
119. Freitas C., Müller R.H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int. J. Pharm. 168:1998;221-229.
120. Freitas C., Müller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 47:1999;125-132.
121. Freitas C., Müller R.H. Stability determination of solid lipid nanoparticles (SLN™) in aqueous dispersion after addition of electrolyte. J. Microencapsulation. 16:1999;59-71.
122. Müller R.H., Olbrich C. Solid lipid nanoparticles (SLN): phagocytic uptake, in vitro cytotoxity and in vivo biodegradation, 1st communication. Pharm. Ind. 61:1999;462-467.
123. Müller R.H., Olbrich C. Solid lipid nanoparticles (SLN): phagocytic uptake, in vitro cytotoxicity and in vivo biodegradation, 2nd communication. Pharm. Ind. 61:1999;564-569.
124. Dingler A., Blum R.P., Niehus H., Gohla S., Müller R.H. Solid lipid nanoparticles (SLN™/Lipiopearls™) - a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J. Microencapsulation. 16:1999;751-767.
125. Cavalli R., Caputo O., Gasco M.R. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur. J. Pharm. Sci. 2000;. in press.
126. Ambarkhane A.V., Gala H.J., Patravale V.B. Submicron Lipopearls of Nimesulide. Abstract Book 4th International Symposium on Innovations in Pharmaceutical Sciences and Technology. 2000;52.